<h2>Papers about in silico identification of kinase hinge binding fragments</h2>
<ol>
   <li>Sydow, D.; Schmiel, P.; Mortier, J.; Volkamer, A. KinFragLib: Exploring the Kinase Inhibitor Space Using Subpocket-Focused Fragmentation and Recombination. J. Chem. Inf. Model. 2020, 60 (12), 6081–6094. https://doi.org/10.1021/acs.jcim.0c00839.</li>
   <li>Rachman, M.; Bajusz, D.; Hetényi, A.; Scarpino, A.; Mero, B.; Egyed, A.; Buday, L.; Barril, X.; Keseru, G. M. Discovery of a Novel Kinase Hinge Binder Fragment by Dynamic Undocking. RSC Med. Chem. 2020, 11 (5), 552–558. https://doi.org/10.1039/c9md00519f.</li>
   <li>Wang, Y.; Sun, Y.; Cao, R.; Liu, D.; Xie, Y.; Li, L.; Qi, X.; Huang, N. In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery. J. Med. Chem. 2017, 60 (20), 8552–8564. https://doi.org/10.1021/acs.jmedchem.7b01075.</li>
   <li>Mukherjee, P.; Bentzien, J.; Bosanac, T.; Mao, W.; Burke, M.; Muegge, I. Kinase Crystal Miner: A Powerful Approach to Repurposing 3D Hinge Binding Fragments and Its Application to Finding Novel Bruton Tyrosine Kinase Inhibitors. J. Chem. Inf. Model. 2017, 57 (9), 2152–2160. https://doi.org/10.1021/acs.jcim.7b00213.</li>
   <li>Xing, L.; Klug-Mcleod, J.; Rai, B.; Lunney, E. A. Kinase Hinge Binding Scaffolds and Their Hydrogen Bond Patterns. Bioorganic Med. Chem. 2015, 23 (19), 6520–6527. https://doi.org/10.1016/j.bmc.2015.08.006.</li>
   <li>Xing, L.; Rai, B.; Lunney, E. A. Scaffold Mining of Kinase Hinge Binders in Crystal Structure Database. J. Comput. Aided. Mol. Des. 2014, 28 (1), 13–23. https://doi.org/10.1007/s10822-013-9700-4.</li>
   <li>Urich, R.; Wishart, G.; Kiczun, M.; Richters, A.; Tidten-Luksch, N.; Rauh, D.; Sherborne, B.; Wyatt, P. G.; Brenk, R. De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments. ACS Chem. Biol. 2013, 8 (5), 1044–1052. https://doi.org/10.1021/cb300729y.</li>
   <li>Zhao, H.; Dong, J.; Lafleur, K.; Nevado, C.; Caflisch, A. Discovery of a Novel Chemotype of Tyrosine Kinase Inhibitors by Fragment-Based Docking and Molecular Dynamics. ACS Med. Chem. Lett. 2012, 3 (10), 834–838. https://doi.org/10.1021/ml3001984.</li>
   <li>Lippert, T.; Schulz-Gasch, T.; Roche, O.; Guba, W.; Rarey, M. De Novo Design by Pharmacophore-Based Searches in Fragment Spaces. J. Comput. Aided. Mol. Des. 2011, 25 (10), 931–945. https://doi.org/10.1007/s10822-011-9473-6.</li>
   <li>Kolb, P.; Kipouros, C. B.; Huang, D.; Caflisch, A. Structure-Based Tailoring of Compound Libraries for High-Throughput Screening: Discovery of Novel EphB4 Kinase Inhibitors. Proteins Struct. Funct. Bioinforma. 2008, 73 (1), 11–18. https://doi.org/10.1002/prot.22028.</p>
   
</ol>

<h2>Some things may be useful</h2>

<ol>
   <li>Yang, Y.; Zhang, Y.; Hua, Y.; Chen, X.; Fan, Y.; Wang, Y.; Liang, L.; Deng, C.; Lu, T.; Chen, Y.; et al. In Silico Design and Analysis of a Kinase-Focused Combinatorial Library Considering Diversity and Quality. J. Chem. Inf. Model. 2020, 60 (1), 92–107. https://doi.org/10.1021/acs.jcim.9b00841.</li>
  <li>Lv, K.; Chen, W.; Chen, D.; Mou, J.; Zhang, H.; Fan, T.; Li, Y.; Cao, D.; Wang, X.; Chen, L.; et al. Rational Design and Evaluation of 6-(Pyrimidin-2-Ylamino)-3,4-Dihydroquinoxalin-2(1 H)-Ones as Polypharmacological Inhibitors of BET and Kinases. J. Med. Chem. 2020, 63 (17), 9787–9802. https://doi.org/10.1021/acs.jmedchem.0c00962.</li>
   <p>We proposed to use the hybridization strategy, which will incorporate the KAc binding moiety with a typical kinase hinge binder to discover novel dual BET-kinase inhibitors. This strategy could enable us to select more biological relevant kinases as BET-kinase polypharmacological targets. To test the hypothesis of the hybrid strategy, we designed four prototype compounds (5−8 in Table 1) by combining the pyrimidin-2-amine group with two KAc mimic and initialized a docking study to check the binding feasibility of them in the first bromodomain of BRD4
(BRD4-BD1). The docking result indicated that the compounds can bind to the KAc binding pocket of BRD4 and maintain the essential hydrogen-bond interactions between the residue Asn140 and the selected dihydroquinoxalin-2(1H)-one18−20 or 3,5-dimethylisoxazole motif21−25 (see the Figure
S1 for the calculated binding conformation).</p>
   <li>Chachulski, L.; Windshügel, B. LEADS-FRAG: A Benchmark Data Set for Assessment of Fragment Docking Performance. J. Chem. Inf. Model. 2020, 60 (12), 6544–6554. https://doi.org/10.1021/acs.jcim.0c00693.</li>
   <li> Jacoby, E.; Wroblowski, B.; Buyck, C.; Neefs, J.; Meyer, C.; Cummings, M. D.; van Vlijmen, H. Protocols for the Design of Kinase-Focused Compound Libraries. Mol. Inform. 2018, 37 (5), 1700119. https://doi.org/10.1002/minf.201700119.</li>
   <li>Drwal, M. N.; Bret, G.; Perez, C.; Jacquemard, C.; Desaphy, J.; Kellenberger, E. Structural Insights on Fragment Binding Mode Conservation. J. Med. Chem. 2018, 61 (14), 5963–5973. https://doi.org/10.1021/acs.jmedchem.8b00256.</li>
   <li>Mucs, D.; Bryce, R. A.; Bonnet, P. Application of Shape-Based and Pharmacophore-Based in Silico Screens for Identification of Type II Protein Kinase Inhibitors. J. Comput. Aided. Mol. Des. 2011, 25 (6), 569–581. https://doi.org/10.1007/s10822-011-9442-0.</li>
   <li>Vieth, M.; Erickson, J.; Jibo, W.; Webster, Y.; Mader, M.; Higgs, R.; Watson, I. Kinase Inhibitor Data Modeling and de Novo Inhibitor Design with Fragment Approaches. J. Med. Chem. 2009, 52 (20), 6456–6466. https://doi.org/10.1021/jm901147e.</li>
   <p>A reconstructive approach based on computational fragmentation of existing inhibitors and validated kinase potency models to recombine and create “de novo” kinase inhibitor small molecule libraries is described. The screening results from model selected molecules from the corporate database and seven computationally derived small molecule libraries were used to evaluate this approach. </p>
</ol>
